LifePlan Financial Group’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

LifePlan Financial Group’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$4K	Hold	1,440	–	–	﹤0.01%	505
2020 Q2	$6K	Hold	1,440	–	–	﹤0.01%	467
2020 Q1	$1K	Hold	1,440	–	–	﹤0.01%	545
2019 Q4	$2K	Hold	1,440	–	–	﹤0.01%	520
2019 Q3	$1K	Hold	1,440	–	–	﹤0.01%	544
2019 Q2	$1K	Sell	1,440 -1	-0.1%	-$2	﹤0.01%	541
2019 Q1	$4K	Hold	1,441	–	–	﹤0.01%	483
2018 Q4	$3K	Hold	1,441	–	–	﹤0.01%	489
2018 Q3	$7K	Hold	1,441	–	–	﹤0.01%	425
2018 Q2	$7K	Hold	1,441	–	–	﹤0.01%	411
2018 Q1	$10K	Hold	1,441	–	–	0.01%	372
2017 Q4	$12K	Hold	1,441	–	–	0.01%	109
2017 Q3	$12K	Hold	1,441	–	–	0.01%	109
2017 Q2	$15K	Hold	1,441	–	–	0.01%	107
2017 Q1	$17K	Hold	1,441	–	–	0.01%	109
2016 Q4	$18K	Hold	1,441	–	–	0.01%	115
2016 Q3	$26K	Hold	1,441	–	–	0.02%	109
2016 Q2	$15K	Hold	1,441	–	–	0.01%	99
2016 Q1	$27K	Hold	1,441	–	–	0.02%	97
2015 Q4	$38K	Hold	1,441	–	–	0.03%	90
2015 Q3	$66K	Hold	1,441	–	–	0.05%	87
2015 Q2	$46K	Hold	1,441	–	–	0.03%	94
2015 Q1	$46K	Hold	1,441	–	–	0.03%	78
2014 Q4	$54K	Hold	1,441	–	–	0.04%	81
2014 Q3	$38K	Hold	1,441	–	–	0.03%	68
2014 Q2	$43K	Hold	1,441	–	–	0.03%	65
2014 Q1	$53K	Hold	1,441	–	–	0.04%	116
2013 Q4	$60K	Hold	1,441	–	–	0.04%	106
2013 Q3	$76K	Hold	1,441	–	–	0.06%	82
2013 Q2	$77K	Buy	+1,441	New	+$72K	0.09%	62

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LifePlan Financial Group's NAVB Position: Q3 2020 in Review

LifePlan Financial Group held its Navidea Biopharmaceuticals Inc. (NAVB) position steady in Q3 2020 at 1,440 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #505.

LifePlan Financial Group first reported a position in NAVB in Q2 2013 and has held it in 30 quarters since. The position peaked at $77K in Q2 2013. 38 funds tracked by Wall St. Rank hold NAVB as of Q3 2020.

LifePlan Financial Group held 1,440 shares of Navidea Biopharmaceuticals Inc. worth $4K as of Q3 2020.
LifePlan Financial Group left its Navidea Biopharmaceuticals Inc. share count unchanged in Q3 2020.
Navidea Biopharmaceuticals Inc. made up ﹤0.01% of LifePlan Financial Group's portfolio in Q3 2020, its #505 holding.
LifePlan Financial Group first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 30 quarters since.
LifePlan Financial Group's Navidea Biopharmaceuticals Inc. position peaked at $77K in Q2 2013.
38 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2020.

Based on LifePlan Financial Group's 13F filing for Q3 2020, filed 30 Oct 2020.